Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site TORONTO, ON / ACCESSWIRE / March 18, 2021 / Novamind Inc., (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly-owned subsidiary, Cedar Clinical Research (“CCR”) has been selected as a key…


Previous articleTryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics
Next articleTy Tashiro joins MINDCURE as the Senior Translational and Psychometric Architect for iSTRYM’s AI-Driven Psychedelic Digital Therapeutic Technology